- Home
- YI vs SER Comparison
YI vs SER Comparison
Compare YI & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- SER
- Stock Information
- Founded
- YI 2010
- SER 2017
- Country
- YI China
- SER United States
- Employees
- YI N/A
- SER N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- SER Health Care
- Exchange
- YI Nasdaq
- SER Nasdaq
- Market Cap
- YI 70.0M
- SER 56.5M
- IPO Year
- YI N/A
- SER 2018
- Fundamental
- Price
- YI $6.75
- SER $5.40
- Analyst Decision
- YI
- SER Strong Buy
- Analyst Count
- YI 0
- SER 2
- Target Price
- YI N/A
- SER $13.00
- AVG Volume (30 Days)
- YI 11.3K
- SER 25.7K
- Earning Date
- YI 08-28-2025
- SER 08-11-2025
- Dividend Yield
- YI N/A
- SER N/A
- EPS Growth
- YI N/A
- SER N/A
- EPS
- YI N/A
- SER N/A
- Revenue
- YI $1,984,717,013.00
- SER $130,000.00
- Revenue This Year
- YI N/A
- SER N/A
- Revenue Next Year
- YI N/A
- SER N/A
- P/E Ratio
- YI N/A
- SER N/A
- Revenue Growth
- YI N/A
- SER N/A
- 52 Week Low
- YI $4.15
- SER $3.81
- 52 Week High
- YI $11.90
- SER $10.28
- Technical
- Relative Strength Index (RSI)
- YI 41.84
- SER 48.70
- Support Level
- YI $6.69
- SER $5.02
- Resistance Level
- YI $6.90
- SER $5.63
- Average True Range (ATR)
- YI 0.18
- SER 0.40
- MACD
- YI -0.01
- SER 0.02
- Stochastic Oscillator
- YI 63.41
- SER 29.03
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.